Market closed
HOOKIPA Pharma Inc/$HOOK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About HOOKIPA Pharma Inc
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Ticker
$HOOK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
165
Website
HOOK Metrics
BasicAdvanced
$44M
Market cap
-
P/E ratio
-$4.11
EPS
0.83
Beta
-
Dividend rate
Price and volume
Market cap
$44M
Beta
0.83
52-week high
$11.30
52-week low
$3.41
Average daily volume
38K
Financial strength
Current ratio
3.857
Quick ratio
3.582
Long term debt to equity
3.94
Total debt to equity
5.691
Interest coverage (TTM)
-508.28%
Management effectiveness
Return on assets (TTM)
-20.10%
Return on equity (TTM)
-48.99%
Valuation
Price to revenue (TTM)
0.838
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-0.564
Growth
Revenue change (TTM)
227.80%
Earnings per share change (TTM)
-54.92%
3-year revenue growth (CAGR)
37.92%
3-year earnings per share growth (CAGR)
-41.40%
What the Analysts think about HOOK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for HOOKIPA Pharma Inc stock.
HOOK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HOOK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HOOK News
AllArticlesVideos
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
GlobeNewsWire·1 week ago
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
GlobeNewsWire·1 week ago
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for HOOKIPA Pharma Inc stock?
HOOKIPA Pharma Inc (HOOK) has a market cap of $44M as of November 08, 2024.
What is the P/E ratio for HOOKIPA Pharma Inc stock?
The price to earnings (P/E) ratio for HOOKIPA Pharma Inc (HOOK) stock is 0 as of November 08, 2024.
Does HOOKIPA Pharma Inc stock pay dividends?
No, HOOKIPA Pharma Inc (HOOK) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next HOOKIPA Pharma Inc dividend payment date?
HOOKIPA Pharma Inc (HOOK) stock does not pay dividends to its shareholders.
What is the beta indicator for HOOKIPA Pharma Inc?
HOOKIPA Pharma Inc (HOOK) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.